NantKwest IPO Research Information

NantKwest IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on NantKwest, and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
NantKwest	NK - NASDAQ	$20.00-$23.00	$25.00	$37.00	8.3 million	7/28/2015
Underwriter(s): BofA Merrill Lynch, Citigroup, Jefferies, Piper Jaffray
Co-Manager(s): MLV & Co.
Industry: Health Care
Filing(s): Filed 2015-06-19 Name Change 2015-07-13 Terms Added 2015-07-16

NantKwest Quote & Chart - Click for current quote - NK

About NantKwest (adapted from NantKwest prospectus):
They are a pioneering clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "NK" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.